Physician profile
Shakeel Uddin
NPI 1548260029
$8,398.14
in general payments reported to CMS, 2019-2025
40 companies · $1,328 in 2025
The $1,328 reported for 2025 was more than what 76% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,219 · 2020: $712 · 2021: $1,065 · 2022: $1,416 · 2023: $1,313 · 2024: $1,345 · 2025: $1,328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,969 · Education: $17.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,968.88 |
| Education | $17.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,186.06 | 2019-2025 | Jot Dx, Aveir, Gallant |
| Boston Scientific Corporation | $774.10 | 2019-2025 | Watchman Flx, Varithena Administration Pack, Bodyguardian |
| Amgen INC. | $461.33 | 2019-2025 | Repatha |
| Merck Sharp & Dohme LLC | $447.92 | 2021-2025 | Verquvo, Capvaxive |
| Janssen Pharmaceuticals, INC | $384.96 | 2019-2023 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $311.78 | 2019-2025 | Lifevest |
| Impulse Dynamics (USA) INC. | $300.81 | 2022-2024 | Optimizer, Optimizer |
| Novo Nordisk INC | $275.31 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Biotronik INC. | $269.39 | 2019-2022 | |
| Tactile Systems Technology INC | $261.58 | 2019-2024 | Flexitouch Plus, Entre Plus |
| E.R. Squibb & Sons, L.L.C. | $170.33 | 2019-2025 | Camzyos, Eliquis |
| Penumbra, INC. | $167.57 | 2019 | |
| Medtronic Vascular, INC. | $147.35 | 2019-2020 | |
| Altathera Pharmaceuticals LLC | $134.74 | 2023 | Sotalol Hydrochloride |
| Novartis Pharmaceuticals Corporation | $126.00 | 2021-2023 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shakeel Uddin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.